biomed devic servic
get readi offens buy
bottom line upgrad ahead view compani
approach apex turnaround cusp multi-year cycl
acceler top-lin growth translat increment leverag opportun
beyond result support view compani report strong
revenu growth across geographi especi strong out-performance
apac yet us/apac knee us hip somewhat off-set continu weak
spine cmf view continu invest improv suppli
chain new product cadenc cultur chang account commercial-
centric focu taken hold compani final posit go
offens suppli chain invest work inventori channel
annual invest sale market top-lin out-performance
begin lead addit leverag opportun improv investor sentiment
multipl expans continu drive stock higher share ytd
still trade signific discount larg cap med-tech peer believ
opportun time begin build posit buy
top line post revenu compar cg/street estim
apac continu strong momentum xfx growth
benefit part stock ahead price/tax chang america also strong
growth us knee us hip outperform
strateg cultur chang pay manag repeatedli note high
level energi excit within sale organ state specif
suppli stabil led grow confid across sale team world-wide
believ clear evid stori get better strategy/
cultur chang becom increasingli visibl across broader organ
remind new ceo came board late focus bulk
attent resolv qualiti suppli issu suppli issu larg
solv quality/ regulatori track acceler pace
new product launch improv sale forc morale/execut prioriti
larg accomplish prioriti follow result manag note
engin focu shift back toward innov prioriti give
increas confid technolog pipelin head
pipelin updat reiter import pipelin product fuel
return sustain top/bottom line growth remind past month
compani significantli bolster product portfolio materi launch knee
persona partial persona cementless persona revis
extrem sidu stemless shoulder comprehens basepl system
well robot rosa knee rosa spine
product fill materi gap portfolio view launch cementless
knee particularli import fill key competit gap vs come price
premium complementari rosa robot applic bottom line
set first time nearli four year commerci
channel equip least product standpoint go offens target
competit account well upsel exist custom premium technolog
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
figur result vs estim consensu
guidanc unchang remind guidanc call top-lin
growth rang flat inclus neg bp fx impact
note like come high end rang impli constant
currenc sale growth y/i pro forma ep expect
guid rang compar cg/consensu
adjust oper margin guid rang line
estim compani adjust tax rate expect
line estim
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma oper net revenu productactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet number us million zimmer biomet hold
chang estim
made follow chang estim
figur summari chang estim
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
rel uncertainti surround remedi suppli issu impact
revenu margin sum maintain pt base price-to-earnings
multipl appli pro-forma ep
biomed devic servic
except ep newold newold newold revenu gross operatin ebitda net zimmer biomet hold
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep ep chg share gener oper rate adjust growth ep ex growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
